VERA NASDAQ
Vera Therapeutics, Inc.
1W: -0.2%
1M: -7.7%
3M: -7.8%
YTD: -38.3%
1Y: +2.6%
3Y: +204.8%
5Y: +77.2%
$29.99
+1.69 (+5.97%)
Weekly Expected Move ±8.1%
$23
$26
$28
$30
$33
Credit Risk of going bust: lower than 63% of companies Debt: 3.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.13 (down 99.6%), Vera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $75.2M against a stock market value of $2.16B.
Distance to default 6.53 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $37.6M (short-term plus half of long-term), stock volatility 61.2%; Altman Z'' -1.67. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.13 (down 99.6%), Vera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $75.2M against a stock market value of $2.16B.
Distance to default 6.53 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $37.6M (short-term plus half of long-term), stock volatility 61.2%; Altman Z'' -1.67. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships5
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2021-09-21
Earliest Filing
2022-09-09
Latest Filing
licensee: 2
partner: 2
target: 1
Counterparties (Filed by VERA)
5 relationshipsCompanies named in VERA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Novartis Pharma AG | NVSEF | licensee | Amendment to License Agreement involving milestone payments and stock issuance. | 2022-09-09 | View |
| Amplyx Pharmaceuticals, Inc. | — | target | Target of asset acquisition for MAU868 assets | 2021-12-17 | View |
| Pfizer Inc. | PFE | partner | Parent company of Amplyx Pharmaceuticals, Inc. | 2021-12-17 | View |
| Novartis Pharma AG | NVSEF | licensee | Licensor of MAU868 rights to Vera Therapeutics | 2021-12-17 | View |
| Novartis International Pharmaceutical AG | NVSEF | partner | Predecessor to Novartis Pharma AG in the license agreement | 2021-12-17 | View |
Mentioned As Counterparty
1 mentionsOther companies that named VERA in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-15 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-10 | Earnings Release; Exhibits | View | |
| 2026-07-09 | Officer/Director Change | View | |
| 2026-07-07 | Other Events | View | |
| 2026-06-02 | Other Events | View | |
| 2026-05-26 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-09 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-18 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-12-10 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-26 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-06 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-05 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Financial St | Agreement | View |
| 2025-06-03 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-06-02 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-19 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR